NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report

Background NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window for reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data of drug safety and combination with other medications especially anticoagulants are heterog...

Full description

Saved in:
Bibliographic Details
Published inThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery Vol. 57; no. 1; pp. 1 - 6
Main Authors Abdul Rashid, Anna Misya’il, Md Noh, Mohamad Syafeeq Faeez, Yusof Khan, Abdul Hanif Khan, Loh, Wei Chao, Baharin, Janudin, Ibrahim, Azliza, Inche Mat, Liyana Najwa, Wan Sulaiman, Wan Aliaa, Hoo, Fan Kee, Hanapiah, Fazah Akhtar, Basri, Hamidon
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 03.11.2021
Springer Nature B.V
SpringerOpen
Subjects
Anticoagulants
Case Report
Case reports
Chinese traditional medication
Elderly
Hepatotoxicity
Medicine
Medicine & Public Health
NeuroAid II
Neurology
Neurosurgery
Polypharmacy
Psychiatry
Stroke
Chinese traditional medication
Stroke
Hepatotoxicity
Elderly
NeuroAid II
Online AccessGet full text

Cover

More Information
Summary:Background NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window for reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data of drug safety and combination with other medications especially anticoagulants are heterogenous. We report a possible case of hepatotoxicity induced by NeuroAid II in combination with anticoagulants. Case presentation We report an elderly patient who developed symptoms of cardioembolic stroke presented outside of time window for reperfusion therapy. He was started on a regiment of statins, anticoagulation, beta blockers and NeuroAid II. One month later he presented with deranged liver enzymes. Cessation of NeuroAid II resulted in rapid improvement of transaminitis within days. Conclusions We wish to highlight the potential harmful effect of administering NeuroAid II with an anticoagulant and the importance of routine follow-up and blood monitoring in the elderly patients with stroke.
ISSN:1110-1083
1687-8329
DOI:10.1186/s41983-021-00397-y